We advised the underwriters on Bristol Myers Squibb Ireland’s inaugural euro issuance

Davis Polk advised the joint lead managers, joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol Myers Squibb Company, consisting of €750 million of 2.973% notes due 2030, €1.15 billion of 3.363% notes due 2033, €1.15 billion of 3.857% notes due 2038, €750 million of 4.289% notes due 2045 and €1.2 billion of 4.581% notes due 2055.

Bristol Myers Squibb Company is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr., counsel Jennifer (Ying) Lan and associate Paul M. Sessa. The tax team included partner Kara L. Mungovan and associates Omar Hersi and Summer Elbardissy. Counsel Michael Comstock and associate Timothy J. Sullivan provided environmental advice. The intellectual property team included partner David R. Bauer and associate Elizabeth Pott. All members of the Davis Polk team are based in the New York office.

Copy link to share post